COMMUNIQUÉS West-GlobeNewswire

-
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
08/01/2018 -
AMAG Pharmaceuticals Announces Preliminary 2017 Financial Results and Provides 2018 Guidance
08/01/2018 -
Athenex Announces Chinese FDA Allowance of Investigational New Drug Application of Oraxol to Begin Clinical Trials
08/01/2018 -
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
08/01/2018 -
Sientra Announces Preliminary Unaudited Fourth Quarter 2017 Revenue
08/01/2018 -
Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH
08/01/2018 -
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
08/01/2018 -
SeaSpine Announces Preliminary Results for Fourth Quarter and Full-Year 2017
08/01/2018 -
BIOSIG TECHNOLOGIES COMPLETES PRIVATE PLACEMENT
08/01/2018 -
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
08/01/2018 -
XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel
08/01/2018 -
IRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year
08/01/2018 -
Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
08/01/2018 -
Microbot Medical Enters into Agreement to Acquire Novel Technology to Enhance Existing Technology Platforms and Strengthen Patent Portfolio
08/01/2018 -
Oncolix Initiates Patient Recruitment of Second Cohort of Prolanta™ Phase 1 Trial in Advanced Ovarian Cancer
08/01/2018 -
Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts
08/01/2018 -
NeuroMetrix Reports Preliminary 2017 Financial Highlights
08/01/2018 -
Inovalon Expects Fourth Quarter Revenue Growth of 18% to 20% and Adjusted EBITDA Growth of 78% Assuming the Midpoint, Consistent with Prior Guidance
08/01/2018 -
AxoGen, Inc. Preannounces Estimated Fourth Quarter and Full Year 2017 Revenue
08/01/2018
Pages